CepTor to Present at the White Mountain Capital Conference Today

CepTor to Present at the White Mountain Capital Conference Today



NEWPORT BEACH, Calif., April 19  /PRNewswire-FirstCall/ -- CepTor, Corp.
(OTC:CEPO) (BULLETIN BOARD: CEPO) , CEO Bill Pursley will be presenting today
at White Mountain Capital's Third Annual Biotechnology Conference, Tuesday
April 19, 2005 at the Rihga Royal Hotel in Midtown, Manhattan.

Mr. Pursley will be speaking on cell-targeted therapeutic products for
neuromuscular and neurodegenerative diseases with emphasis on muscular
dystrophy at 4pm in the Broadway Suite, Room 508.  For more information or to
register for the conference please visit:
http://whitemountaincapital.com/ConferenceAd2005/

In an earlier company release today, the company announced that intellectual
property filings have been made to further strengthen its patent position for
the Company's muscle cell targeted protease inhibitor platform technology.

About CepTor Corporation

CepTor Corporation is a biopharmaceutical company focusing on the development
of proprietary, cell-targeted therapeutic products for neuromuscular and
neurodegenerative diseases.  The Company's mission is to increase the quality
and quantity of life of people suffering with these diseases.  CepTor's primary
efforts are currently being focused on moving its lead product, MYODUR, into
phase I/II clinical trials for Duchenne's muscular dystrophy.  The Company's
broad platform technology also includes the development of products for
multiple sclerosis, retinal degeneration and epilepsy.

    CONTACTS:
    Don Fallon, CFO
    CepTor Corporation
    [phone]  Fax [phone]

    Nicole Mittelstaedt
    Director of Communications
    InvestSource Inc.
    [phone]



This news release contains forward-looking statements.  Such statements are
valid only as of today, and we disclaim any obligation to update this
information.  These statements are subject to known and unknown risks and
uncertainties that may cause actual future experience and results to differ
materially from the statements made.  These statements are based on our current
beliefs and expectations as to such future outcomes.  Drug discovery and
development involve a high degree of risk.  Factors that might cause such a
material difference include, among others, uncertainties related to the ability
to attract and retain partners for our technologies, the identification of lead
compounds, the successful preclinical development thereof, the completion of
clinical trials, the FDA review process and other government regulation, our
pharmaceutical collaborator's ability to successfully develop and commercialize
drug candidates, competition from other pharmaceutical companies, product
pricing and third party reimbursement. 

DATASOURCE: CepTor Corporation



CONTACT:  Don Fallon, CFO of CepTor Corporation, [phone], fax,

[phone]; or Nicole Mittelstaedt, Director of Communications of

InvestSource Inc., [phone], for CepTor Corporation



Web site:  http://whitemountaincapital.com/ConferenceAd2005 

Copyright